Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout

Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market—and to add blockbuster sales to a portfolio that’s at the heart of Takeda’s $62 billion buyout.